Reuters logo
BRIEF-Alexion Pharmaceuticals names David Brennan interim CEO
December 12, 2016 / 12:44 PM / a year ago

BRIEF-Alexion Pharmaceuticals names David Brennan interim CEO

Dec 12 (Reuters) - Alexion Pharmaceuticals Inc:

* Alexion’s board of directors announces new leadership appointments

* David Brennan, Alexion board member and former CEO of Astrazeneca Plc, named interim CEO

* Brennan succeeds David Hallal who has resigned for personal reasons

* Hallal has also resigned from board

* Alexion Pharmaceuticals Inc says David Anderson, former CFO of Honeywell, joins Alexion as CFO

* Company expects to file Q3 10-Q in January 2017 or earlier

* Alexion Pharmaceuticals - audit and finance committee investigation to date not identified facts that require co to update previously reported results

* Spencer Stuart has been engaged to commence search for a permanent CEO Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below